Dr. Phioanh Nghiemphu, MD

Dr. Nghiemphu practices at Peter Morton UCLA Medical Building in Los Angeles, California.

Dr. Nghiemphu's NPI, 1871519017, was assigned on July 14, 2006. Dr. Nghiemphu graduated from Albert Einstein College of Medicine in 1999. Dr. Nghiemphu holds California license A73835.

Dr. Nghiemphu's primary practice is Peter Morton UCLA Medical Building, at 200 Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 794-9206.

Dr. Nghiemphu's primary practice is Peter Morton UCLA Medical Building in Los Angeles, California. Dr. Nghiemphu is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Nghiemphu to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nghiemphu practices, 4 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Nghiemphu's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Nghiemphu is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Nghiemphu's licenses on file in 2 states: California and Nevada.

Dmand AI lists epilepsy and seizures among the conditions Dr. Nghiemphu treats.

CMS data shows 164 Medicare services from Dr. Nghiemphu across 3 procedure codes in 2024, all of them office visits, for 88 Medicare patients. Medicare paid $17,448 for them.

CMS counts 88 Medicare patients who saw Dr. Nghiemphu in 2024. The largest group is 65 to 74, with 35 patients. 55% of them have high blood pressure, and 52% have high cholesterol. 42% are also on Medicaid. Their average risk score is 1.65, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nghiemphu's median patient age at 47, with 53% women.

In 2024, Dr. Nghiemphu wrote 242 Medicare Part D claims for 37 patients. 90% of them were for generic drugs. CMS names the drug for 122 of them, across 6 drugs with 11 or more claims each, at $256,360 in total drug cost. In 2023, CMS named 135 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Nghiemphu for performance year 2024, reported as part of a group. Dr. Nghiemphu accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Nghiemphu as offering telehealth.

Dmand AI links 16 papers to Dr. Nghiemphu, published from 2011 to 2025. 2023 was the busiest year, with 3. Dr. Nghiemphu has published most often in J Clin Oncol. Dr. Nghiemphu's most frequent co-authors are Timothy Francis Cloughesy, MD, Robert Arthur Chong, MD, PhD and Dusica Babovic-Vuksanovic, MD.

Dmand AI links Dr. Nghiemphu to 5 clinical trials, 3 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Gliosarcoma, Glioblastoma and Glioma. Jonsson Comprehensive Cancer Center sponsors the most, 2.

CMS Open Payments shows 121 general payments to Dr. Nghiemphu from 6 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 45% of the total. SpringWorks Therapeutics, Inc. paid the most, $84,144.

Dr. Nghiemphu graduated from Albert Einstein College of Medicine in 1999. Dr. Nghiemphu is a member of AAN and Society for Neuro-Oncology.

Dr. Nghiemphu is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.